Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT101 (Nespecabtagene Autoleucel) in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
NCT05338931Phase 2Recruiting
- Sponsor
- AbClon
- Start
- Mar 2022
- Primary completion
- Mar 2030
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of nespecabtagene autoleucel in B-cell non-Hodgkin lymphoma, sponsored by AbClon. Started Mar 2022; status: recruiting.
02
Drugs
nespecabtagene autoleucel
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05338931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05338931.